Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 13, Issue 4, Pages 511-518Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2013.05.018
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Associazione Italiana per la Ricerca sul Cancro (FIRC)
Ask authors/readers for more resources
Despite the initial skepticism, targeted therapies represent a new perspective in the treatment of cancer. Tyrosine kinases, and in particular receptor tyrosine kinases (RTKs), are considered ideal targets for this type of therapy. MET, the tyrosine kinase receptor for the Hepatocyte Growth Factor (HGF), has recently become a very interesting and studied target in oncology. In this review we discuss firstly 'why' the MET/HGF pathway can be considered a target in human tumors; secondly 'where' MET/HGF inhibition can be useful in cancer treatment and finally 'how' MET and HGF can be inhibited using either monoclonal antibodies or tyrosine kinase inhibitors. We also highlight some questions in the anti-MET/HGF targeted therapy field that are still waiting for an answer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available